|
ADH5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
7.80090436691694E-11 |
| Normal-vs-Stage3 |
1.62436730732907E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
2.188300E-02 |
| Stage1-vs-Stage3 |
3.757000E-01 |
| Stage1-vs-Stage4 |
5.90859999999305E-05 |
| Stage2-vs-Stage3 |
1.009760E-02 |
| Stage2-vs-Stage4 |
4.0315000000013E-05 |
| Stage3-vs-Stage4 |
1.098220E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.04916075827077E-13 |
| Normal-vs-Asian |
<1E-12 |
| Caucasian-vs-AfricanAmerican |
5.828400E-01 |
| Caucasian-vs-Asian |
4.042600E-01 |
| AfricanAmerican-vs-Asian |
9.471600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
4.323800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
5.51899999999828E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.781600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.192200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.019800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.347200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.111600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.869000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.060300E-02 |
| Classical-VS-Follicular |
1.819540E-03 |
| Classical-VS-Other |
7.492800E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
3.96550000000273E-05 |
| Tall-VS-Other |
6.539400E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
2.366200E-01 |
| Follicular-VS-Normal |
1.64523950019202E-12 |
| Other-VS-Normal |
3.76509999999719E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
2.26589999999804E-05 |
|
|
